We recently published a list of 10 Most Undervalued S&P 500 Stocks to Buy Now. In this article, we are going to take a look ...

We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are ...

In October 2023, the US regulator approved the combination of BRAFTOVI and Mektovi for treating metastatic non-small cell lung cancer (NSCLC). Pfizer holds exclusive rights to BRAFTOVI in Canada ...

The three-drug regimen – based on Array BioPharma/Pierre Fabre’s BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) along with Eli Lilly’s EGFR-targeted antibody E ...

BEACON CRC also included another three drug arm – Braftovi, Erbitux, and MEK inhibitor Mektovi (binimetinib) from Array Biopharma (now part of Pfizer). That wasn’t able to improve survival any ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi – encorafenib – in combination with ...

Pfizer (NYSE:PFE) reported positive topline results from a Phase 3 study of its drug Braftovi, also known as encorafenib, in the treatment of a certain type of colorectal cancer. The study ...

BRAFTOVI in combination with cetuximab and mFOLFOX6 showed statistically significant and clinically meaningful improvement in progression-free survival and overall survival in patients with ...

The randomized multicenter trial examined the combination of encorafenib (Braftovi, Pfizer) and cetuximab (Erbitux, Imclone) in the front-line setting with chemotherapy for the treatment of BRAF ...